Items Tagged ‘dacomitinib’

December 9th, 2014

Dacomitinib Shows Activity in Selected Patients With Advanced Non-Small Cell Lung Cancer


In a phase II trial reported in The Lancet Oncology, doctors from Dana Farber Cancer Institute in Boston found that treatment of patients with advanced non–small cell lung cancer (NSCLC) with EGFR mutations or clinical characteristics associated with response to EGFR inhibitors with the targeted pan-HER inhibitor dacomitinib was promising. A targeted therapy is one […]

View full entry

Tags: dacomitinib, Lung Cancer, Lung Cancer - Non-Small Cell, News, non-small cell lung cancer, nsclc, Recurrent Lung Cancer - Non-Small Cell, Stages IIIB-IV Lung Cancer - Non-Small Cell